Applied Materials (NASDAQ: AMAT ) currently trades near $539, roughly 48% below the $800 threshold, after pulling back from its 52-week high of $739.67. The strongest bullish factors include surging AI-driven wafer fab equipment (WFE) demand, management's raised calendar 2026 semiconductor equipment growth outlook above 30%, and Applied Materials' dominant position in deposition, etch, and advanced packaging tools.

AZTA fell -11.5% during regular trading, sliding from Friday's $37.40 close to about $33.10. The selloff was triggered by the abrupt resignation of CEO John Marotta, announced Monday morning.

RGNX is down roughly -23.6% to $8.19 from a prior close of $10.72, with the selloff beginning in premarket trading and extending into Monday's regular session. The move was triggered by the FDA placing a clinical hold on RGX-121, the company's Hunter syndrome (MPS II) gene therapy, after asymptomatic spine MRI findings in five CAMPSIITE study participants.

FCEL is down -10.13% to $17.56 during regular Monday trading, sliding from last Friday's $19.54 close. The move reflects a sector-wide rotation out of high-beta, cash-burning fuel-cell and hydrogen names, with no company-specific announcement today.

SNDK fell -9.92% to about $1,438, extending a decline that began in premarket trading. Primary catalyst: strong fiscal Q4 results (revenue +372% YoY) were overshadowed by softer FQ1 revenue guidance of $10.3–10.8B, missing top-end consensus and stoking fears of slowing NAND price growth.

AXTI is trading down roughly -11.68% during the regular session, near $62.48 versus Friday's $70.74 close, after sliding pre-market. The primary catalyst is a broad optical-connectivity selloff driven by co-packaged optics (CPO) concerns.

AAOI is trading down -17.54% to $102.93 during Monday's regular session, extending a premarket slide of roughly -12% after a Friday after-hours filing. The primary catalyst is a newly disclosed $600 million at-the-market equity offering through Raymond James and Needham, its third ATM raise this year, sparking dilution concerns.

OABI rose +0.70% (+$0.03) to close at $4.33 during Friday's regular trading session, extending a multi-day advance. The move continues momentum from the Aug. 17 Eli Lilly collaboration and license agreement, which offers up to $370M in milestone payments plus tiered royalties.

Silence Therapeutics shares rose roughly 20% over the 30-day period, driven by positive clinical data and a major capital raise. The biggest catalyst was positive Phase 2 topline results for divesiran in polycythemia vera, which sent the stock up about 29% in a single session to a 52-week high.

Achieve Life Sciences (ACHV) rose roughly 31% over the last 30 days, from a closing price near $6.10 in late July to about $7.99 by late August. The gain extended a broader advance of approximately 70% over the past three months, driven by progress on the company's cytisinicline regulatory pathway.

PaySign (PAYS) shares climbed roughly 62% over the 30-day period, rising from an adjusted close of $8.69 to about $14.09. The move was driven primarily by better-than-expected second-quarter 2026 results reported on August 5, 2026, including a 48% year-over-year revenue increase and a raised full-year outlook.

VREX closed up +0.11% (+$0.02) at $18.51 in Friday's regular session, the latest completed session before Monday's open. The gain reflects consolidation, with shares pinned just below the $18.90 per-share all-cash Teledyne Technologies acquisition offer (~$1.1 billion, announced Aug. 10).

PUBM shares climbed roughly 30% in the last 30 days, rising from a closing price of $12.65 on July 22, 2026, to $16.41 on August 21, 2026. The move was driven by better-than-expected Q2 2026 results reported August 6: revenue of $78.6 million (up 11% year over year) and adjusted EPS of $0.12 versus a consensus estimate near a loss.

SOPH rose +3.84% to close at $8.65 in the latest completed session, up +$0.32 from the prior close of $8.33. The move occurred during regular market hours, extending a rally that carried shares to a fresh 52-week high (intraday high $8.68).

MTW shares rose roughly 37% over the last 30 days, climbing from $14.37 to $19.68, driven primarily by a stronger-than-expected second-quarter 2026 earnings report. Adjusted EPS of $0.46 significantly exceeded the $0.11 consensus estimate, while net sales rose 10% year over year to $595 million.

CTNM rose +7.30% in the latest regular session, closing at $17.19 (from a $16.02 prior close) and touching a new 52-week high of $17.35. The rally extended a multi-week uptrend tied to lead asset PIPE-791 (LPA1 antagonist), now in the global Phase 2 PROPEL-IPF trial for idiopathic pulmonary fibrosis.

SGMT shares climbed roughly 45% over the last 30 days, from a closing price near $7.07 in late July to $10.25 by the August 21 close. The move extends a broader rally, with the stock up more than 40% over the trailing quarter and roughly 73% year to date.

Mistras Group (MG) shares climbed roughly 21% over the trailing 30 days, rising from about $15.64 to $18.96 on the back of strong second-quarter results. The rally was driven by better-than-expected Q2 2026 earnings, record adjusted EBITDA, and raised full-year guidance.

Delcath Systems (DCTH) climbed roughly 40% over the past 30 days, rising from about $12.22 to $17.14. The rally was driven by stronger-than-expected second-quarter 2026 results, reported before the open on August 6, 2026.

SPIR closed up +0.36% to $13.94 during Friday's regular session, a modest gain from the prior close of $13.89. The move was low-conviction: shares opened higher at $14.16 but faded through a $13.69–$14.40 range on light volume (about 432K vs. roughly 1.1M average).